Assistant Professor, Department of Cancer Biology
Vanderbilt University Medical Center, Nashville, USA
Department of Biological Sciences
Tennessee State University, USA
Department of Biochemistry and Cancer Biology, Meharry Medical College
Submit manuscript at Online Submission System or send as an e-mail attachment to the Editorial Office at email@example.com
Table of Contents
About the Journal
Journal of Tumor Research is an open access, peer-reviewed journal.
It is obvious why open access and open data portals would be beneficial to the public: free information and more of it is empowering to society. The diversity of information available in Open Access also makes it possible for Scholars and other information users to have wide access to more information.
The journal covers the diagnosis, classification, and treatment of tumors. The major purpose of this journal is to publish clinically relevant information that will directly improve the care of patients with cancers and tumors. The journal welcomes original significant and up-to-date articles on all aspects of Cell tumor, Circulating tumor, Brain tumor, Neuroendocrine tumor, Tumor necrosis, Tumor microenvironment, Tumor DNA, Stromal tumors, Fibrous tumors, Tumor supressors, Wilms tumor, Tumor lysis, and related subjects like Oncology, Cancer biology and Radiology.
Being an academic journal, it provides an opportunity to share the information among medical scientists and researchers in the form of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide
The journal is using Editorial Tracking for online manuscript submission, review and tracking systems. Editorial board members of the Journal of Tumor Research or outside experts review the manuscripts submitted; at least two independent reviewer’s approval followed by the editor is required for the acceptance of any citable manuscript.
Fast Editorial Review Process
is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
Articles published in Journal of Tumor Research have been cited by esteemed scholars and scientists all around the world. Journal of Tumor Research has got h-index 4 , which means every article in Journal of Tumor Research has got 4 average citations.
Current Issue Highlights
Soft-Tissue Tumor Reporting and Data System (ST-RADS): MRI Reporting Guideline with Multi-Institutional Validation Study of Musculoskeletal Extremity Tumors
Avneesh Chhabra*, Rajendra Kumar, William Murphy, Alexandra Callan, Marwa Zaid, Yin Xi, Parham Pezeshk, Uma Thakur, Gitanjali Bajaj, Raghu Ratakonda, Oganes Ashikyan and Behrang Amini
Potential Late Effects in survivors of childhood cancers.
Chimeric antigen receptor T cells in cancer immunotherapy: Beyond CD19.
Saad S Kenderian